new broker report, page-5

Conclusion section of the RM Wise report from the site...

Also interesting to note that this is the 3rd Buy recommendation and the 1st since RM merged with Wise owl... increased credibility???



RMWise Research believes the personal Wheezeomoter™ has the potential to be a “cash cow” for KSX and capture significant market share in a rapidly growing market. The Wheezemoter™ is the only portable device in the world which can be used by asthma patients and their family to accurately assess wheeze activity. The product is to be sold in pharmacies as an OTC product with or without prescriptions. The product will also be sold to pharmaceutical companies in clinical studies to validate drugs and also to GPs, asthma
nurses, paediatricians and emergency physicians.
The revenue model for the Wheezeomoter™ is impressive and a major retail ramp-up of the product could provide significant free cash flows to KarmelSonix. Assuming a wholesale price of $100 per unit, the Company would receive $1,000,000 for every 10,000 units sold. Whilst unit sales are difficult to quantify, sales of Wheezometer™ could be substantial considering
the captive market that exists globally from concerned parents and caregivers. In excess of 6 million children have Asthma in the US and there are currently no products in the marketplace for home use which can effectively monitor wheezing in young children.

RMWise Research considers the KarmelSonix’ product offering offers plenty of leverage for investors into a market which has to date been neglected by major medical device companies.
There is significant market growth potential in the diagnosis and management of asthma through non-invasive means. KarmelSonix’ product offering addresses the needs of a highly captive market which places great value on the ability to be able to effectively monitor and diagnose asthma in children, the elderly and disabled. RMWise Research rates KarmelSonix
Limited as a Speculative Buy.